All News

2018

June

Media Release / Jun 01, 2018

Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine

Read More

May

Media Release / May 18, 2018

Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention

Read More
Media Release / May 15, 2018

Novartis successfully completes acquisition of AveXis, Inc.

Read More

April

Media Release / Apr 20, 2018

New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients

Read More
Media Release / Apr 19, 2018

Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer

Read More
Media Release / Apr 19, 2018

Novartis delivered a strong first quarter and acted to become a more focused medicines company

Read More
Media Release / Apr 17, 2018

Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures

Read More
Media Release / Apr 09, 2018

Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader

Read More

March

Media Release / Mar 23, 2018

Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

Read More
Media Release / Mar 07, 2018

Novartis expands alliance with Science 37 to advance virtual clinical trials program

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More